Bakhos A. Tannous, PhD - Research in molecular Imaging, gene transfer technologies and high throughput screening to develop novel therapeutics against brain tumors.
- Lab phone 1: 617-726-6027
- Lab phone 2: 617-643-3485
Research Investigator Profile
Bakhos A. Tannous, PhD
- Associate Professor,
Harvard Medical School
- Associate Neuroscientist,
Massachusetts General Hospital
- Director, Vector Production and
The Tannous’ laboratory focuses on developing molecular biosensors which reports from tumors environment. Recently, we characterized a novel luciferase from the marine copepod Gaussia princeps (Gaussia luciferase or Gluc) which is the smallest luciferase known (19.9 kDa) and much more sensitive than the ones currently in use. This luciferase is naturally secreted and therefore its expression can be monitored over time by assaying an aliquot of the conditioned medium for its activity. We showed that tumor growth and response to therapy, efficiency of gene transfer as well as stem cell survival and proliferation can be monitored in vivo by assaying few microliters of blood for the Gluc activity. Based on this secreted Gluc, we are currently developing different molecular probes which are activated strictly in the tumor environment and can be monitored both in the blood and/or localized in the animal using in vivo bioluminescence imaging.
Another aspect of Dr. Tannous’ research is to target brain tumors using different gene transfer technologies. We have engineered a reporter protein which is metabolically biotinylated by endogenous mammalian biotin ligase and presents biotin on the tumor cell surface. This reporter allows for non-invasive real time imaging of any cell type transduced to express it in culture or in vivo with labeled streptavidin moieties and different imaging modalities including fluorescence molecular tomography (FMT), positron emission tomography (PET) and magnetic resonance (MR). Currently, we are translating this technology to in vivo applications hoping to achieve more sensitive methods for diagnosis, monitoring of brain tumors and more effective therapeutic modalities which can selectively target brain tumor cells by virtue of biotin-streptavidin system in combination with different therapies.
Our laboratory also focuses on high throughput screening for drugs which acts specifically against brain tumor stem-like cells. Based on the naturally secreted Gluc, we have developed a high-throughput screening assay which allows monitoring of cell viability and to study drug kinetics specifically in tumor stem cells. We have obtained some interesting drug “hits” which we are currently validating in culture as well as in our in vivo primary human invasive brain tumor models. We have also showed that Gluc secretion can be used as a marker for protein secretion as well as endoplasmic reticulum (ER)-stress, a hallmark of many neurological disorders. We found that human fibroblasts from Parkinson as well as Dystonia patients have a defect in processing of Gluc and are much more sensitive to ER-stress as compared to normal fibroblasts. We are currently screening for drugs which restore protein processing and/or alleviate the ER stress in these patient cells.
Read more about Dr. Tannous' research laboratory: Tannous Lab: Experimental Therapeutics and Molecular Imaging Laboratory
|Research interests||Gene therapy to brain tumors; drug screening; glioblastoma animal models; molecular imaging|
|Research techniques||Molecular biology; viral vector development; brain tumors animal models; primary glioblastoma models; glioblastoma stem-like cells in vitro and in vivo models|
|Diseases studied||Brain tumors, including glioblastoma|
|NCBI PubMed link||
|Lab mailing address||Neuroscience Center
Molecular Neurogenetics Unit
149 13th St., room 6101
Charlestown, MA 02129